Belichick named University of North Carolina's head coach Sportscategory· December 12, 2024 U.S. drugmaker Amgen said on Thursday it will invest $1 billion in a second manufacturing facility in ...

In North Carolina, Amgen is building a new pharmaceutical facility in Holly Springs. In Florida, we are working on a new Amazon facility in Palm City. In Texas and Austin, we are working on an ...

Houston has new lab space to welcome life sciences researchers and investment, but it's also making sure to get its workforce ...

The first group of apprentices has officially signed on with Amgen in a unique program that will prepare a skilled workforce for the biopharmaceutical leader's planned expansion in Wake County. Wake ...

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

RBC Capital analyst Gregory Renza maintained a Buy rating on Amgen (AMGN – Research Report) yesterday and set a price target of $320.00. The company’s shares closed yesterday at $289.02.

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...